Skip to main content

LYRA

Stock
Health Care
Biotechnology

Performance overview

LYRA Price
Price Chart

Forward-looking statistics

Beta
0.45
Risk
89.22%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Company info

SectorHealth Care
IndustryBiotechnology
Employees79
Market cap$19.5M

Fundamentals

Enterprise value$13.5M
Revenue$1.2M
Revenue per employee
Profit margin0.00%
Debt to equity861.47

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$60.50
Dividend per share
Revenue per share$0.90
Avg trading volume (30 day)$11M
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth-0.6
Credit+2.3
Liquidity+0.8
Inflation+0.4
Commodities+2.1
Interest Rates+0.5

Valuation

Dividend yield0.00%
PEG Ratio-12.16
Price to sales12.14
P/E Ratio-12.16
Enterprise Value to Revenue11.39
Price to book3.06

Upcoming events

Next earnings dayAugust 12, 2025
Next dividend day
Ex. dividend day

News

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (June 12, 2025)
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics, Inc.  LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).

Benzinga (June 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free